7 results
10-K
2023 FY
SLRN
Acelyrin, Inc.
28 Mar 24
Annual report
4:21pm
by blocking mast cell proliferation and reducing the degranulation of mast cells, limiting their toxic cellular products from being released
424B4
SLRN
Acelyrin, Inc.
5 May 23
Prospectus supplement with pricing info
4:22pm
their toxic cellular products from being released into the circulation. SLRN-517 is fully human and has demonstrated high potency against the target
S-1/A
EX-1.1
SLRN
Acelyrin, Inc.
1 May 23
IPO registration (amended)
6:10am
, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances
S-1/A
SLRN
Acelyrin, Inc.
1 May 23
IPO registration (amended)
6:10am
proliferation and reducing the degranulation of mast cells, limiting their toxic cellular products from being released into the circulation. SLRN-517
S-1
ycfp5le
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
gtay3n
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next